These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38031003)

  • 41. The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.
    Chen W; Li L; Cheng S; Yu J
    Dis Markers; 2022; 2022():2631852. PubMed ID: 36061356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
    Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P
    Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.
    Huo G; Liu W; Chen P
    BMC Cancer; 2023 Feb; 23(1):143. PubMed ID: 36765356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.
    Fitzsimmons TS; Singh N; Walker TDJ; Newton C; Evans DGR; Crosbie EJ; Ryan NAJ
    Front Med (Lausanne); 2023; 10():1192762. PubMed ID: 37250628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study.
    Xu B; Cheng H; Li K; Lv Y; Zeng X; Liu T; Yu W; Guo W
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3029-3038. PubMed ID: 34973080
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer.
    Guo L; Liang J; Dai W; Li J; Si Y; Ren W; Lu Y; Chen D
    Cancer Control; 2022; 29():10732748221107590. PubMed ID: 35673884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
    Mutlu H; Bozcuk H; Artaç M; Eser İ
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S6-S11. PubMed ID: 37147977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Wang Y; Lau W; Li Y; Tian Y; Lei Y; Wang J; Xia F
    Int J Surg; 2023 Nov; 109(11):3590-3601. PubMed ID: 37598406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis.
    Liu X; Guo CY; Tou FF; Wen XM; Kuang YK; Zhu Q; Hu H
    Int J Cancer; 2020 Jul; 147(1):116-127. PubMed ID: 31633798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis.
    Shen X; Huang S; Xiao H; Zeng S; Liu J; Ran Z; Xiong B
    Eur J Hosp Pharm; 2023 Jan; 30(1):3-8. PubMed ID: 34497128
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials.
    Wankhede D; Hofman P; Grover S
    J Cancer Res Clin Oncol; 2023 May; 149(5):2179-2189. PubMed ID: 35984491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review.
    Yang YL; Li ZQ; Wang QL; Gu JJ; Fang XJ; Huang GH
    Clin Ther; 2021 Nov; 43(11):1997-2012. PubMed ID: 34794831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
    Aghajanian C; Filiaci V; Dizon DS; Carlson JW; Powell MA; Secord AA; Tewari KS; Bender DP; O'Malley DM; Stuckey A; Gao J; Dao F; Soslow RA; Lankes HA; Moore K; Levine DA
    Gynecol Oncol; 2018 Aug; 150(2):274-281. PubMed ID: 29804638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
    Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50.
    Chen W; Chen J; Zhang L; Cheng S; Yu J
    BMC Cancer; 2023 Aug; 23(1):791. PubMed ID: 37612622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis.
    Qian D; Xu Y; Wu Y; Qiu J; Hong W; Meng X
    Chin Med J (Engl); 2023 Jul; 136(14):1663-1670. PubMed ID: 37279392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.